Oncology

The indication’s expansion for palbociclib to include male patients is based upon data from postmarketing reports and electronic health records showing that the safety profile for men treated with the drug is consistent with the safety profile in women treated with this medication.

The daratumumab (Darzalex) combination therapy would be the first for use in the frontline setting for transplant-eligible patients with multiple myeloma.

Although lung cancer screenings are covered at no cost by most insurers, state Medicaid programs are not required to offer coverage for this service.

In this clip, Jamie Fritz, RPh, Retail Pharmacy Manager at Compass Oncology, explains the treatment support kit committee of the National Community Oncology Dispensing Association and how these kits are designed for each specific patient.

Top news of the day from across the health care industry.

The combination therapy reduced the risk of squamous cell carcinoma development on the face and scalp by approximately 75% in the study.

According to the study, enzyme USP15 may regulate cancer cell response to poly-(ADP-ribose) polymerase inhibitors.

Study finds chronic hepatitis C virus infection should not delay the initiation of an urgent cancer therapy.

A phase 3 study compared overall survival and cardiac safety between biosimilar trastuzumab (Ontruzant) and the reference medicine.

When combined, treatment with metformin and heme suppressed tumor growth in mice.

A pilot study suggests compounds found in coffee may slow the growth of prostate cancer.

A simple, compact laser probe is an opportunity for early detection of melanoma, the deadliest form of skin cancer.

This approval is based on results from the Phase III IMpower133 study, which showed that atezolizumab in combination with chemotherapy helped people live significantly longer compared to chemotherapy alone in the intention-to-treat population.

Top news of the day from across the health care industry.

Study provides insight into how prostate cancer transitions to an aggressive, treatment-resistant subtype following anti-androgen therapy.

Trastuzumab is indicated for the treatment of human epidermal growth factor receptor-2 (HER2) overexpressing breast cancer and HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.

PARP inhibitors used alongside immunotherapy may help stimulate the immune response to cancer cells by attracting immune cells to the tumor.

Cheryl Allen, BSPharm, MBA, Vice President of Industry Relations at Diplomat Pharmacy, talks about new therapeutic developments going on within the prostate cancer space.

With this approval, atezolizumab plus nab-paclitaxel is the first cancer immunotherapy regimen to be approved for breast cancer.

Atezolizumab (Tecentriq) plus chemotherapy is approved under the FDA’s Accelerated Approval Program, which allows conditional approval of a medicine that fills an unmet medical need for a serious or life-threatening disease or condition.

Patient-driven recommendations to reduce breast cancer-related economic burden could be key to shaping policies and interventions.

Venetoclax (Venclexta) plus obinutuzumab (Gazyva) is being developed for patients with previously-untreated chronic lymphocytic leukemia and co-existing medical conditions.

Feel More Like You was developed in collaboration with Look Good, Feel Better Foundation, the leading cancer support organization focusing attention on the appearance and beauty needs of cancer patients, and Cancer Support Community, the largest professionally led, nonprofit network of cancer support worldwide.

Cheryl Allen, BSPharm, MBA, Vice President of Industry Relations at Diplomat Pharmacy, discusses the rapidly changing oncology market and what to look for in the drug pipeline.

Top news of the week from Specialty Pharmacy Times.

This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.

Trastuzumab and hyaluronidase-oysk (Herceptin Hylecta, Genentech) is indicated for subcutaneous administration in certain patients with HER2-positive early and metastatic breast cancer.